S

Sir Steve Jackson

Founding Partner
💼 Partner bei Ahren Innovation Capital →
Über

Sir Steve is the Originator of Olaparib/Lynparza, recently partnered by AstraZeneca with Merck and valued as an asset at up to $17BN, and used to treat 140,000 patients worldwide with ovarian, breast, pancreatic and prostate cancer. He is a repeat entrepreneur, and most recently founded Adrestia Therapeutics with Ahren in 2018, an early-stage drug discovery platform, which was acquired by Insmed Inc in 2023. Sir Steve is the University of Cambridge Frederick James Quick Professor of Biology. He is Senior Group Leader at the Cancer Research UK Cambridge Institute and Associate Group Leader at the Gurdon Institute. He is a leading expert in the field of DNA repair and DNA-damage signalling and invented Lynparza, the world’s first marketed DNA-repair enzyme inhibitor, an effective treatment of breast and other cancers. Sir Steve’s awards include the Johann Anton Merck Award (2022), Royal Society Mullard Award (2020), Heineken Prize for Science by the Royal Netherlands Academy of Arts and Science (2016) and the UK GSN Medal for his contributions to the field of genome stability. He is a fellow of the Royal Society and a member of EMBO.

Schwerpunkte

BioTech, HealthTech

Region

📍 Ansässig in Cambridge

Verifizierte Kontakte & Outreach Agenten

Direktes E-Mail-Muster

[email protected] | [email protected]

KI Outreach Agenten Pitch Writer

Erstelle personalisierte Anschreiben basierend auf den genauen Investitionskriterien...

Direkten Partnerkontakt freischalten

Erhalte Zugriff auf verifizierte Kontakte und nutze unseren Outreach Composer, um Anschreiben in Sekundenschnelle zu entwerfen.

Über GRID kontaktieren

100% kostenloses Konto · Start in 1 Klick